PMHNP Scope of Practice for General Psychiatry in Michigan

If you’re a psychiatrist or psychiatric nurse practitioner, you’ve probably asked yourself this question a dozen times: ‘Can I legally prescribe Adderall, benzos, or buprenorphine through telehealth—or am I one misstep away from a DEA audit?’

You’re not alone. The rules around prescribing controlled substances via telemedicine have been in constant flux since COVID. Federal waivers. State-specific carve-outs. Proposed DEA rules that never materialized. It’s enough to make anyone second-guess writing that ADHD prescription after a video visit.

Here’s the straight answer: Yes, you can prescribe controlled substances via telehealth in 2026—but only if you understand the federal DEA rules, your state’s specific telehealth laws, and your scope of practice as a psychiatrist or PMHNP. And those rules vary wildly depending on where your patient is located.

Let’s break down what’s actually happening right now, what’s changing, and how you stay compliant while serving patients who desperately need your care.

The Current State of Play: DEA Extensions Through 2026

As of January 2, 2026, the DEA and HHS announced a fourth extension of COVID-era telehealth flexibilities for controlled substances—now running through December 31, 2026. This means you can continue prescribing Schedule II–V medications (stimulants, benzodiazepines, buprenorphine, etc.) via telemedicine without requiring an initial in-person exam, as long as you conduct a proper evaluation via two-way audio-video.

This extension prevents care disruptions while the DEA finalizes permanent telemedicine rules. But—and this is critical—these are temporary rules. The DEA is actively working on new permanent regulations that will likely require either:

• An in-person exam within a specific timeframe (e.g., 6 months for buprenorphine), or
• A Special Telemedicine Registration for certain providers (more on this below)

What the Extension Actually Allows

Under the current temporary policy:

• New patients you’ve never seen in person: You can prescribe controlled substances after a telehealth evaluation via live video (audio-only generally isn’t sufficient, except for buprenorphine in some cases).
• Existing patients you’ve seen in person: No federal restrictions on telehealth prescribing for follow-ups. The Ryan Haight Act’s in-person requirement is already satisfied.
• Patients seen in person by any provider: If your patient had an in-person visit with another clinician (even outside your practice), you can prescribe via telehealth with no federal telemedicine-specific limits.

The key: document your evaluation thoroughly. Mental status exam, detailed history, clinical justification for the medication. This isn’t just covering your bases—it’s the standard of care and what regulators will look for if questions arise.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

What’s Coming: DEA’s Proposed Permanent Rules

In January 2025, the DEA announced three proposed rules to replace the temporary extensions. Here’s what matters for psychiatrists and PMHNPs:

1. Buprenorphine Expansion for OUD Treatment

The DEA is proposing to allow 6 months of buprenorphine treatment via telehealth (including audio-only consultations) before requiring an in-person visit. This is huge for addiction psychiatry—it acknowledges that telehealth works for MAT and shouldn’t be artificially restricted.

After those 6 months, you’d need to conduct (or arrange) an in-person evaluation to continue prescribing.

2. Special Telemedicine Registration

Here’s the big one: The DEA is proposing a Special Telemedicine Prescriber Registration that would allow certain providers to prescribe controlled substances to new patients via telehealth—indefinitely, without any in-person requirement.

For Schedule III–V medications, any qualified prescriber could apply for this registration. But for Schedule II substances (stimulants, some opioids), the DEA is initially limiting eligibility to:

• Board-certified psychiatrists
• Hospice and palliative care physicians
• Long-term care facility physicians
• Pediatricians (in limited cases)

Psychiatrists are explicitly included. If this rule is finalized as proposed, you could obtain this registration and legally prescribe Adderall, Ritalin, and other Schedule II medications via telehealth to patients you’ve never met in person—as long as you conduct an appropriate evaluation and meet the standard of care.

This would be a game-changer for telepsychiatry, especially in underserved areas where patients can’t easily access in-person psychiatric care.

3. Platform Registration & National PDMP

The DEA also wants to require telehealth platforms to register with the DEA for the first time. This is a response to well-publicized cases of overprescribing by some telemedicine startups.

The proposal also calls for a national Prescription Drug Monitoring Program (PDMP) to integrate data across states, making it easier to spot doctor-shopping and diversion.

Bottom line: More administrative steps for platforms and providers, but clearer legal pathways for compliant telehealth prescribing.

State Laws: Where the Real Complexity Lives

Federal DEA rules set the floor, but states can impose stricter requirements—and many do. If you’re practicing telehealth across state lines (or even just in one restrictive state), you need to know the local rules.

Florida: Psychiatric Carve-Out for Schedule II

Florida explicitly prohibits prescribing Schedule II controlled substances via telehealth—unless it’s for:

• Psychiatric disorder treatment
• Inpatient hospital care
• Hospice care
• Nursing home residents

Translation: You can prescribe Adderall for ADHD or other psychiatric conditions via telehealth in Florida, but you cannot prescribe Schedule II opioids for chronic pain remotely. Document the psychiatric indication clearly.

Florida also allows out-of-state providers to register for telehealth practice without a full Florida license—but you must still follow Florida’s controlled substance rules.

Texas: NPs Can’t Prescribe Schedule II Outpatient

Texas law is strict for nurse practitioners: PMHNPs cannot prescribe Schedule II medications (like stimulants) outside of hospital or hospice settings, period. Even with a supervising physician.

For outpatient ADHD management via telehealth in Texas, you need a psychiatrist (MD/DO) to write the prescription. This is a hard limit that trips up many telehealth platforms.

Texas does allow telehealth prescribing by physicians (including psychiatrists) without an in-person visit for mental health conditions, but you must use real-time audio-video. And you’re required to check the Texas Prescription Monitoring Program before prescribing opioids, benzos, barbiturates, or carisoprodol.

California: CURES Checks Every 4 Months

California is telehealth-friendly: no in-person requirement for prescribing via telemedicine as long as you meet the standard of care.

But California has one of the strictest PDMP mandates in the country: You must check the CURES database before prescribing Schedule II–IV controlled substances to a new patient, and every 4 months for ongoing treatment.

California also mandates 100% e-prescribing for all prescriptions (with rare exceptions), so paper scripts are out.

New York: PDMP Checks for Every Schedule II–IV Rx

New York’s I-STOP law requires checking the state Prescription Monitoring Program before every Schedule II, III, or IV controlled substance prescription. Every refill. Every time.

New York also mandates e-prescribing for all prescriptions (controlled and non-controlled) since 2016. But the state is telehealth-friendly overall: video exams are sufficient to establish a patient relationship, and experienced PMHNPs (>3,600 hours) can practice fully independently—including prescribing controlled substances.

Pennsylvania & Illinois: Fewer State-Level Restrictions

Both Pennsylvania and Illinois generally defer to federal law on telehealth prescribing. They require PDMP checks (Pennsylvania for opioids and benzos; Illinois for all controlled substances), but don’t impose blanket telehealth bans on specific drug schedules.

Illinois offers a Full Practice Authority license for experienced PMHNPs (4,000+ hours), though even those NPs must consult with a physician for ongoing Schedule II opioid or benzodiazepine prescriptions beyond 30 days—a quirk in the law.

Pennsylvania requires PMHNPs to have collaborative agreements with physicians for all prescriptive authority. There’s no independent practice pathway yet.

Psychiatrist vs. PMHNP: Scope of Practice Matters

This is where things get real: your ability to prescribe controlled substances via telehealth depends heavily on whether you’re a psychiatrist (MD/DO) or a psychiatric nurse practitioner—and which state your patient is in.

Psychiatrists (MD/DO): Full Authority Nationwide

As a licensed physician, you have full independent prescribing authority for controlled substances in every state (assuming you’re licensed and have a DEA registration). No supervision. No collaborative agreements. You can prescribe Schedule II–V medications as clinically appropriate.

Your only limits are:

• State-specific telehealth rules (like Florida’s psychiatric carve-out)
• PDMP and e-prescribing mandates
• Standard-of-care requirements

PMHNPs: State-by-State Variability

Psychiatric Mental Health Nurse Practitioners face a patchwork of state regulations:

Full Practice States (New York, California by 2026):

• Experienced PMHNPs can practice independently, including prescribing controlled substances
• California requires 3+ years in supervised settings first; New York requires 3,600 clinical hours

Reduced Practice States (Pennsylvania, Illinois):

• PMHNPs need collaborative agreements with physicians
• Can prescribe controlled substances under physician supervision
• Illinois limits continuous Schedule II prescribing without physician consultation

Restricted Practice States (Texas, Florida):

• PMHNPs must work under physician supervision
• Texas NPs cannot prescribe Schedule II medications for outpatient psychiatric care at all
• Florida requires collaborative agreements; psych NPs don’t qualify for autonomous practice

If you’re a PMHNP joining a telehealth platform, know your state’s scope rules. A platform operating in Texas needs psychiatrists on staff to handle ADHD medications. A platform in New York can fully utilize independent PMHNPs.

The Economics: Why Telehealth Prescribing Matters for Your Practice

Let’s talk real numbers. Acquiring new psychiatric patients through traditional marketing channels is expensive:

• Google Ads for mental health keywords: $15–40+ per click. Most clicks don’t book. Realistic cost per booked patient: $200–400+ when you factor in optimization, failed campaigns, and no-shows.
• SEO: Takes 6–12 months of consistent investment before generating meaningful patient flow. Great long-term, but most solo practitioners don’t have the budget or expertise.
• Directory listings (Psychology Today, Zocdoc): Monthly subscription fees + per-booking charges ($35–100+). You compete with hundreds of other providers on the same page.

DIY marketing can eventually pay off—if you have $3,000–5,000/month to spend, the patience to wait 6+ months for results, and the expertise to manage campaigns effectively.

For most providers (especially those starting out or scaling), that’s a big gamble.

Platforms like Klarity Health use a pay-per-appointment model: you only pay a standard listing fee when a pre-qualified patient books with you. No upfront marketing spend. No monthly subscriptions. No wasted ad budget on clicks that don’t convert.

The value proposition is simple:

• Pre-qualified patients already matched to your specialty and availability
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule—only pay when you see patients

Instead of gambling $5,000/month on marketing with uncertain ROI, you pay only for actual patient appointments. That’s guaranteed ROI vs. risk.

And with the ability to prescribe controlled substances via telehealth under current federal rules—and potentially indefinitely under proposed DEA regulations for psychiatrists—you can serve patients who genuinely need psychiatric medication management but can’t access in-person care.

Compliance Checklist: Staying Safe While Prescribing via Telehealth

Here’s your practical compliance roadmap:

Federal Requirements

• [ ] Ensure you have a valid DEA registration in each state where patients are located
• [ ] Use two-way audio-video for initial controlled substance evaluations (audio-only only for buprenorphine in limited cases)
• [ ] Document thoroughly: mental status exam, history, clinical justification for controlled substance
• [ ] Complete the 8-hour MATE Act training on substance use disorder and pain management (required for DEA renewal as of 2023)
• [ ] Use e-prescribing systems with two-factor authentication (DEA-compliant)

State-Specific Requirements

• [ ] Verify you’re licensed in the state where the patient is physically located
• [ ] Check your state’s PDMP (Prescription Drug Monitoring Program) before prescribing controlled substances:
• California: First time + every 4 months
• New York: Every prescription
• Texas: Before opioids, benzos, barbiturates, carisoprodol
• Florida, Pennsylvania, Illinois: Before initial controlled substance Rx
• [ ] Follow state telehealth prescribing rules:
• Florida: Only prescribe Schedule II for psychiatric indications
• Texas: Physicians only for outpatient Schedule II (NPs restricted)
• California: 100% e-prescribing
• [ ] If you’re a PMHNP, ensure you meet your state’s scope requirements:
• Collaborative agreements where required
• Full Practice Authority license if available
• Awareness of prescribing limits (Texas Schedule II ban, Illinois consultation requirements, etc.)

Best Practices

• [ ] Obtain informed consent for telehealth (document patient’s understanding and agreement)
• [ ] Maintain HIPAA-compliant telehealth platform
• [ ] Have a plan for emergency situations (know where patient is located, local emergency resources)
• [ ] Schedule appropriate follow-ups—especially for new patients on controlled substances
• [ ] Stay updated on DEA rule changes (subscribe to DEA and state medical board alerts)

FAQ: Common Questions from Psychiatry Providers

Q: Can I prescribe Adderall to a new patient I’ve only seen via video?

A: Yes, under current federal DEA rules (extended through December 31, 2026), you can prescribe Schedule II stimulants like Adderall after a telehealth evaluation—as long as you:

• Conduct a proper clinical evaluation via two-way audio-video
• Document the encounter thoroughly
• Are licensed and have a DEA registration in the patient’s state
• Follow your state’s specific telehealth prescribing laws (e.g., in Florida, ensure it’s for a psychiatric indication)

Q: What happens after December 31, 2026?

A: The DEA is expected to finalize permanent telemedicine rules before then. Based on January 2025 proposals, psychiatrists may be able to obtain a Special Telemedicine Registration to continue prescribing Schedule II substances via telehealth indefinitely. Other options may include an in-person visit requirement within a certain timeframe (e.g., 6 months).

Q: Do I need a separate DEA number for each state?

A: Yes. You need a DEA registration tied to an address in each state where you prescribe controlled substances to patients. Some providers maintain multiple state DEA registrations if they practice telehealth across state lines.

Q: Can I prescribe buprenorphine via telehealth for opioid use disorder?

A: Yes. The X-waiver was eliminated in 2023—any DEA-registered prescriber can prescribe buprenorphine for OUD without a special waiver. Under proposed DEA rules, you could prescribe buprenorphine via telehealth (even audio-only) for up to 6 months before requiring an in-person visit.

Q: I’m a PMHNP in Texas. Can I prescribe ADHD medications via telehealth?

A: No. Texas law prohibits nurse practitioners from prescribing Schedule II controlled substances (like stimulants) for outpatient care. You would need a supervising physician to write those prescriptions, or the patient would need to see a psychiatrist (MD/DO).

Q: What if my state requires an in-person exam for controlled substances?

A: Some states have laws stricter than federal rules. For example, if a state mandates an in-person physical exam before prescribing certain controlled substances, you must follow that requirement—even though federal law currently allows telehealth-only under the extension. Always comply with the most restrictive applicable rule (state vs. federal).

The Bottom Line: Telehealth Prescribing Is Here to Stay—If You Do It Right

The regulatory landscape for prescribing controlled substances via telehealth is evolving, but the trajectory is clear: telehealth psychiatry isn’t going away. Federal and state policymakers recognize that mental health care—especially for underserved populations—depends on telemedicine access.

As a psychiatrist or PMHNP, you can take advantage of current flexibilities (extended through 2026) and prepare for likely permanent pathways that will allow compliant telehealth prescribing indefinitely—especially if you’re a board-certified psychiatrist eligible for the proposed Special Telemedicine Registration.

But you must stay informed:

• Know your state’s specific rules
• Check PDMPs before prescribing
• Document evaluations thoroughly
• Use compliant e-prescribing systems
• Understand your scope of practice (especially if you’re a PMHNP practicing in a restricted state)

And if you’re looking to grow your practice without the headache and expense of DIY marketing—spending months on SEO, burning cash on Google Ads, or competing on crowded directory sites—platforms like Klarity Health offer a smarter path: pre-qualified patients, built-in telehealth infrastructure, and a pay-per-appointment model that guarantees ROI.

You focus on what you do best: providing excellent psychiatric care. Klarity handles patient acquisition.

Ready to join a platform that handles the marketing so you can focus on patients? Explore Klarity Health’s provider network and see how telehealth psychiatry can grow your practice—compliantly, profitably, and sustainably.

Citations

1. U.S. Department of Health and Human Services. ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026.’ January 2, 2026. https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. U.S. Drug Enforcement Administration. ‘DEA Announces Three New Telemedicine Rules to Continue Open Access to Vital Care.’ January 16, 2025. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. Akerman LLP. ‘Harmonizing Federal and Florida Laws on Prescribing Controlled Substances Through Telehealth.’ March 2023. https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html

4. Texas Medical Board. ‘Prescriptive Authority and Supervision FAQs.’ Updated 2024. https://www.tmb.texas.gov/resources/for-applicants-and-licensees/prescribing-and-supervision

5. Substance Abuse and Mental Health Services Administration (SAMHSA). ‘Elimination of the DATA Waiver (X-Waiver) Requirement.’ Updated 2023. https://www.samhsa.gov/medications-substance-use-disorders/waiver-elimination-mat-act

Source:

• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=WASHINGTON%E2%80%94JANUARY%202%2C%202026%E2%80%94The%20U,while%20permanent%20rules%20are%20finalized
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=Expansion%20of%20Buprenorphine%20Treatment%20via,Telemedicine%20Encounter
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=registration%20is%20available%20to%20medical,V%20medications
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=For%20the%20first%20time%20online,being%20of%20patients
• https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access#:~:text=In%20developing%20these%20rules%2C%20DEA,person%20by%20the%20medical%20provider
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=telehealth%20to%20prescribe%20schedules%20III,one%20of%20the%20following%20categories
• https://www.jdsupra.com/legalnews/states-and-feds-signal-big-changes-to-9301791/#:~:text=of%20Ohio%E2%80%99s%20new%20telehealth%20prescribing,substance%20use%20disorder%20treatment%2C%20is
• https://www.akerman.com/en/perspectives/hrx-harmonizing-federal-and-florida-laws-on-prescribing-controlled-substances-through-telehealth.html#:~:text=No%20special%20registration%20is%20required,the%20State%20to%20do%20so
• https://www.tebra.com/theintake/checklists-and-guides/legal-and-compliance/nurse-practitioner-laws-by-state#:~:text=,start%20their%20own%20medical%20practices